Narciclasine suppresses esophageal cancer cell proliferation and migration by inhibiting the FAK signaling pathway. 2022

Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
Chemical Biology Research Center at School of Pharmaceutical Sciences, Wenzhou Medical University, 1210 University Town, Wenzhou, Zhejiang, 325035, China; Research Institute of Pharmaceutical Sciences, College of Pharmacy, Chonnam National University, Gwangju, 61186, South Korea.

Esophageal cancer (EC) is one of the malignant cancer with pool survival due to the limited therapeutic and drug-resistance. Narciclasine, a natural compound from Lycoris sanguinea possesses antitumor and anti-inflammatory properties. However, the mechanisms underlying the growth-inhibitory effect of narciclasine against EC have not yet been elucidated. Experimental evidences indicated that narciclasine treatment significantly affected the distribution of FAK and its phosphorylation, resulting in proliferation inhibition and migration inhibition of EC. Our study also showed that narciclasine treatment triggered DNA damage and inhibited DNA replication, leading to cell cycle arrest and apoptosis. Further mechanistic studies indicated that narciclasine inhibited EC cell proliferation and migration through FAK/JNK and p38 pathway. Altogether, these findings suggest that narciclasine could be a potential novel chemotherapeutic agent for esophageal cancer cell proliferation and migration.

UI MeSH Term Description Entries
D010617 Phenanthridines
D002465 Cell Movement The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell. Cell Migration,Locomotion, Cell,Migration, Cell,Motility, Cell,Movement, Cell,Cell Locomotion,Cell Motility,Cell Movements,Movements, Cell
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D047151 Amaryllidaceae Alkaloids Alkaloids derived from TYRAMINE combined with 3,4-dihydroxybenzaldehyde via a norbelladine pathway, including GALANTAMINE, lycorine and crinine. They are found in the AMARYLLIDACEAE plant family. Benzazepine-Type Amaryllidaceae Alkaloids,Galanthamine-Type Amaryllidaceae Alkaloids,Norbelladine-Type Amaryllidaceae Alkaloids,Alkaloids, Amaryllidaceae,Amaryllidaceae Alkaloids, Benzazepine-Type,Amaryllidaceae Alkaloids, Galanthamine-Type,Amaryllidaceae Alkaloids, Norbelladine-Type,Benzazepine Type Amaryllidaceae Alkaloids,Galanthamine Type Amaryllidaceae Alkaloids,Norbelladine Type Amaryllidaceae Alkaloids
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular

Related Publications

Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
April 2017, Molecular medicine reports,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
October 2019, Science China. Life sciences,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
December 2017, Cancer biomarkers : section A of Disease markers,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
May 2021, Chemico-biological interactions,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
October 2023, European journal of pharmacology,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
May 2019, BMC cancer,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
January 2022, Journal of oncology,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
October 2020, International journal of molecular medicine,
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
July 2023, Medical oncology (Northwood, London, England),
Yinda Qiu, and Bo Fang, and Nguyen Thi Thanh Thuy, and Aoding Li, and Hee Min Yoo, and Xiaohui Zheng, and Namki Cho
June 2023, Immunopharmacology and immunotoxicology,
Copied contents to your clipboard!